• Our Mission
    • Overview
    • Leadership
  • Science & Technology
    • CoreX™
    • AlloChem™
    • Mine™
  • Pipeline
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • SEDAR+ Filings
    • Stock Information
    • Leadership
    • Investor FAQ
    • Email Alerts

Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update

Aug 28, 2026 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – August 28, 2026) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”), announces the release of its unaudited condensed...

Sharp Therapeutics Announces Closing of Non-Brokered Private Placement

Jul 29, 2026 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – July 29, 2026) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”) is pleased to announce that it has closed its previously...

Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders

Jul 21, 2026 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – July 21, 2026) – Sharp Therapeutics Corp. (TSXV: SHRX) (“Sharp” or the “Company”), a pre-clinical biotechnology company developing small molecule therapies to...

Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update

Jul 15, 2026 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – July 15, 2026) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”) is pleased to announce that it is arranging a non-brokered...

Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date

Jun 30, 2026 | Press Releases

Shareholders Must Recast Their Votes to be CountedPittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – June 30, 2026) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”) announces that...

Sharp Therapeutics Presents New Preclinical Data Supporting Novel Small-Molecule Therapeutic Approach for Niemann-Pick Disease Type C

May 28, 2026 | Press Releases

Novel lead small molecules demonstrate substantial reduction of cholesterol accumulation in NPC patient-derived fibroblasts, with additional data supporting lysosomal health and cellular signaling NPC represents a significant new pipeline opportunity for Sharp,...
« Older Entries

Recent Posts

  • Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update
  • Sharp Therapeutics Announces Closing of Non-Brokered Private Placement
  • Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders
  • Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update
  • Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date

Recent Comments

No comments to show.

Stay connected

  • Our Mission
    • Overview
    • Leadership
  • Science & Technology
    • CoreX™
    • AlloChem™
    • Mine™
  • Pipeline
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • SEDAR+ Filings
    • Stock Information
    • Leadership
    • Investor FAQ
    • Email Alerts
  • Follow
  • Follow
  • Follow

© Sharp Therapeutics Corp. All Rights Reserved.